DE69628921D1 - Verfahren zur modulation der t-zell-überlebensrate durch von bcl-xl protein-spiegels - Google Patents

Verfahren zur modulation der t-zell-überlebensrate durch von bcl-xl protein-spiegels

Info

Publication number
DE69628921D1
DE69628921D1 DE69628921T DE69628921T DE69628921D1 DE 69628921 D1 DE69628921 D1 DE 69628921D1 DE 69628921 T DE69628921 T DE 69628921T DE 69628921 T DE69628921 T DE 69628921T DE 69628921 D1 DE69628921 D1 DE 69628921D1
Authority
DE
Germany
Prior art keywords
cell
bcl
protein
mirrors
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69628921T
Other languages
English (en)
Other versions
DE69628921T2 (de
Inventor
H June
B Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
US Department of Navy
Original Assignee
Arch Development Corp
US Department of Navy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/481,739 external-priority patent/US6143291A/en
Application filed by Arch Development Corp, US Department of Navy filed Critical Arch Development Corp
Application granted granted Critical
Publication of DE69628921D1 publication Critical patent/DE69628921D1/de
Publication of DE69628921T2 publication Critical patent/DE69628921T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
DE69628921T 1995-05-04 1996-05-02 Verfahren zur modulation der t-zell-überlebensrate durch von bcl-xl protein-spiegels Expired - Lifetime DE69628921T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43551895A 1995-05-04 1995-05-04
US435518 1995-05-04
US08/481,739 US6143291A (en) 1995-05-04 1995-06-07 Methods for modulating T cell survival by modulating bcl-XL protein level
US481739 1995-06-07
PCT/US1996/006203 WO1996034956A1 (en) 1995-05-04 1996-05-02 Methods for modulating t cell survival by modulating bcl-xl protein level

Publications (2)

Publication Number Publication Date
DE69628921D1 true DE69628921D1 (de) 2003-08-07
DE69628921T2 DE69628921T2 (de) 2004-04-22

Family

ID=27030576

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69628921T Expired - Lifetime DE69628921T2 (de) 1995-05-04 1996-05-02 Verfahren zur modulation der t-zell-überlebensrate durch von bcl-xl protein-spiegels

Country Status (7)

Country Link
EP (1) EP0826043B1 (de)
JP (2) JPH11504814A (de)
AT (2) ATE244305T1 (de)
AU (1) AU5673496A (de)
CA (1) CA2220012C (de)
DE (1) DE69628921T2 (de)
WO (1) WO1996034956A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780891A1 (fr) * 1998-07-10 2000-01-14 Univ Paris Curie Echange de lymphocytes t
AU1241100A (en) * 1998-10-30 2000-05-22 University Of Nebraska-Lincoln Trans-species transfer of apoptotic genes and transgenic plants developed thereby
CA2464228C (en) 2000-10-27 2017-01-17 Immuno-Rx, Inc. Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
EP2234642B8 (de) * 2007-11-28 2017-11-01 IRX Therapeutics, Inc. Verfahren zur verstärkung einer immunologischen wirkung
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
DK2510106T3 (en) 2009-12-08 2018-05-28 Irx Therapeutics Inc PROCEDURE FOR REVERSING IMMUNE EXPRESSION OF LANGERHANS CELLS
US20230302054A1 (en) * 2019-02-08 2023-09-28 DNA Twopointo Modification of t cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods

Also Published As

Publication number Publication date
CA2220012C (en) 2007-10-30
EP0826043B1 (de) 2003-07-02
CA2220012A1 (en) 1996-11-07
DE69628921T2 (de) 2004-04-22
JPH11504814A (ja) 1999-05-11
AU5673496A (en) 1996-11-21
EP0826043A1 (de) 1998-03-04
WO1996034956A1 (en) 1996-11-07
ATE393634T1 (de) 2008-05-15
JP2008101003A (ja) 2008-05-01
ATE244305T1 (de) 2003-07-15

Similar Documents

Publication Publication Date Title
DE69713499D1 (de) Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
ATE413386T1 (de) Ppar-gamma modulatoren
DE60129799D1 (de) Verfahren zur steigerung des haarwuchses durch wnt polypeptid
ATE110412T1 (de) Translation von mrna.
DE69316057D1 (de) Verfahren zur Bewertung der Permeabilität von Lagerstätten mit neuronalen Netzwerken
DE60224275D1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
KR950700323A (ko) 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 아미노아세틸머캅토아세틸아미드 유도체(Aminoacetylmercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE)
DK0703788T3 (da) Stabiliseret phenylalaninammoniaklyase
DE69628921D1 (de) Verfahren zur modulation der t-zell-überlebensrate durch von bcl-xl protein-spiegels
ATE232191T1 (de) Verfahren und zusammensetzung zur inhibierung der polymerisierung von ethylenisch ungesättigten kohlenwasserstoffen
FI951511A0 (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
NO20010389L (no) Modulering av multippel linje kinase proteiner
DE69513305T2 (de) Vorrichtung zur kompensierung von nichtlinearen merkmalen von magnetoresistiven köpfen
DE69326777D1 (de) Verfahren zur hemmung der viralen morphogenese
ATE499445T1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
DE3872632D1 (de) Vorrichtung zur diebstahlsicherung von autostereoanlagen.
DE69715013T2 (de) S-alkylisothiouronium-derivate enthaltende pharmazeutische zusammensetzungen
DE69420960T2 (de) Mittel zur Verhinderung von Belagbildung, Zusammensetzungen dieses enthaltend und Anwendungsverfahren für Polymerisationsprozesse
DE69420104T2 (de) Verfahren zur Bewertung von wasserstoffabsorbierenden Legierungen für Elektroden.
DE69016249D1 (de) Verfahren zur elektrochemischen Behandlung von Schwefelwasserstoff enthaltendem Gas.
DE59813303D1 (de) Disaccharidderivate zur behandlung von hyperglykämien
GR3034043T3 (en) Fireproof sealing system based on molten adhesives and process for the flameproof sealing of objects or apertures
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
DE69918302D1 (de) Verfahren zur inaktivierung von viren
DE69417600D1 (de) Verfahren zur Stabilisierung der Antigenität von Myeloperoxidase

Legal Events

Date Code Title Description
8364 No opposition during term of opposition